Antiviral Drug Development: How NanoViricides is Overcoming Challenges to the Current Model
As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. NanoViricides discusses their nanotechnology with a different approach to develop and deliver antiviral drugs that can also rescue drugs with delivery and PK/PD problems.
As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed.
In this podcast, Anil Diwan, President and Executive Chairman of NanoViricides Incorporated, explains some of the shortcomings of the current model of antiviral drug development and how NanoViricides developed a nanotechnology with a different approach to develop and deliver antiviral drugs. Anil also presents an overview of the scientific and clinical development of NanoViricides lead program, NV-387 as well as potential applications in different indications.
For more information about NanoViricides Incorporated, visit NanoViricides.com.
For more information about the annual PODD drug delivery conference, please visit Drug-Delivery.org.
Speakers
Related Podcasts
View All
Beyond LNPs: Delivering Genetic Medicines with Novel Vehicles
Biogen's Nicole Murphy on Drug Delivery Innovation and the Acquisition of Alcyone Therapeutics
Balancing Between Concentration and Volume when Developing Patient-Centric Biologics
